SS
CYCN icon

SBI Securities’s Cyclerion Therapeutics CYCN Stock Holding History

SBI Securities’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11
Closed -$32 – 4215
2025
Q2 		$32 Hold
11
– – ﹤0.01% 3812
2025
Q1 		$28 Hold
11
– – ﹤0.01% 3782
2024
Q4 		$35 Buy
+11
New +$31 ﹤0.01% 3708

Other funds holding CYCN

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SBI Securities's CYCN Position: Q3 2025 in Review

SBI Securities sold out of Cyclerion Therapeutics (CYCN) in Q3 2025, closing a stake of 11 shares — an estimated $32 sold.

SBI Securities first reported a position in CYCN in Q4 2024 and held it in 3 quarters. The position peaked at $35 in Q4 2024. 17 funds tracked by Wall St. Rank hold CYCN as of Q3 2025.

  • SBI Securities reported no remaining Cyclerion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 11 Cyclerion Therapeutics shares in Q3 2025, an estimated $32.
  • SBI Securities first reported a position in Cyclerion Therapeutics in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Cyclerion Therapeutics position peaked at $35 in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.